|
Sales for the first half of the year rose by 5% CER, driven by demand for medicines and diagnostics.
|
 |
|
BSV’s branded product portfolio spans women's health, fertility and critical care.
|
|
|
The approval is based on data from the Phase III BENEGENE-2 clinical trial of DURVEQTIX.
|
|
|
Ipsen will pay $111m in cash and equity upfront to gain the global rights, excluding the US, to Day One’s paediatric glioma therapy, Ojemda.
|
|
|
Sandoz launched the biosimilar of J&J’s Stelara in Europe in partnership with Samsung Bioepis to treat psoriasis and Crohn’s disease.
|
|
|
JNJ-2056 is being investigated in the Phase IIb ReTain study which enrols participants who are yet to show Alzheimer’s symptoms.
|
|
|
A Phase II study for ConSynance’s triple monoamine reuptake inhibitor CSTI-500 is slated to begin in 2025.
|
|
